BioGaia

Regulatory Filings • Jan 13, 2017

Press Release 13 January 2017

BioGaia's probiotic to be launched in Thailand

BioGaia has signed an exclusive agreement with Abbott for the rights to commercialize BioGaia products in the area of paediatrics and gastroenterology in Thailand. The products will be co-branded under BioGaia and Abbott brand. Launch of the products is planned to 2017.

BioGaia primarily focus on paediatrics, gastroenterology and oral health and the probiotic products are available in around 90 countries.

"We have a strong focus on growing our Asian business and I am very pleased that BioGaia's products will be available in another important country in the region. Based on the positive experience we already have in collaborating with Abbott in Latin America, I look forward to a successful launch of our products with Abbott in Thailand as well", says Axel Sjöblad, Managing Director, BioGaia.

For additional information please contact Axel Sjöblad, Managing Director, telephone: +46 8 555 293 00

Latest press releases from BioGaia

2016-12-07	BioGaia associated MetaboGen starts study on Intrahepatic Cholestasis of Pregnancy with Ferring
2016-12-05	BioGaia signs major distribution and license agreements with partner in Japan
2016-11-30	BioGaia makes further investment in MetaboGen

This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08 am CET on 13 January 2017.

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. biogaia.com